Figure 2. Parametric Fittings of PFS and OS for Ibrutinib All-Patient ITT Population
This study was conducted by Janssen and Evidera.
METHODS
• A health state model was developed to simulate health outcomes in patients with R/R MCL. The model consisted of three key health states, PFS, post-progression survival (PPS), and death ( Figure 1) . Patients in the PFS phase were stratified according to response in order to capture the utility impacts of treatment response in sensitivity analysis. In the PPS state, the model accounted for a small proportion of patients receiving a subsequent treatment and the associated utility benefit, but it was assumed that subsequent treatment had no impact on overall survival (OS). A discount rate of 3.5% was used. • A Matching Adjusted Indirect Comparison (MAIC) was conducted to adjust for differences in baseline characteristics between PCYC-1104 and relevant published trials given the absence of head-to-head efficacy data. The analysis was used to adjust response, PFS, and OS outcomes. Kaplan-Meier plots of PFS and OS data from published trials were digitized and used to derive hazard ratios (HRs) versus ibrutinib.
• Because PFS and OS are not fully captured in clinical trials, long-term extrapolation of these outcomes was achieved by fitting parametric functions to the PFS and OS Kaplan-Meier data in the PCYC-1104 trial. OS and PFS of comparators were informed by applying the HRs derived from the MAIC analysis to ibrutinib's PFS and OS. The technique of extrapolating trial outcomes using parametric fittings is well accepted by HTA bodies such as NICE 4 .
• Baseline utility and utility across the PFS state were based on QLQ-C30 data from the PCYCY-1104 trial that was mapped using a published algorithm to derive EQ-5D scores. Disutilities due to progression or adverse events and a utility increment due to PFS in the subsequent treatment phase were based on published sources.
• Extensive sensitivity analyses were conducted to test uncertainty around the projection of OS and PFS and to test alternative assumptions regarding utilities.
RESULTS
• Very few comparative trials were identified in the systematic literature review, making a network meta-analysis unfeasible. The systematic literature review also revealed a paucity of data relevant for modeling purposes for BR and R-CHOP. It was not possible to conduct an MAIC adjustment for FCM/R given small sample sizes (n=24 in each arm) of the FCM/R trial. MAIC for bortezomib 5 cannot fully adjust the trial population differences: the Fisher trial enrolled patients who had received only one prior line of treatment (compared to a median of three prior therapies in PCYC-1104), which led to a worse HR for PFS comparing bortezomib to ibrutinib but a better HR for OS after MAIC. The HRs of ibrutinib versus temsirolimus 6 are estimated to be 0.56 (95% CI 0.37-0.84) for PFS and 0.58 (95% CI 0.37-0.90) for OS after MAIC.
• Projected LYs and QALYs were compared between ibrutinib and temsirolimus since the Hess (2009) trial was the most comparable to PCYC-1104 6 .
• Figure 2 presents the results of the PFS and OS KM parametric curve fittings for ibrutinib. As illustrated, all parametric fittings were relatively similar when fitting the within-trial data. However, longer-term projections past the trial data resulted in variations, introducing uncertainty. • Probabilistic sensitivity analysis indicates that when considering uncertainty, ibrutinib's LY benefit remains robust (Figure 3 ).
LIMITATIONS AND CONCLUSIONS
• Comparative data for therapies in this indication are very scarce and no network meta-analysis was possible. Due to the high degree of heterogeneity in patient populations and trial outcomes, comparisons across trials are unreliable and subject to bias.
• Matching-adjusted indirect comparison can help adjust for the variations in patient population across trials, allowing for better comparison of outcomes, but this technique cannot correct for all heterogeneity.
• Due to the paucity of comparative data and the great heterogeneity in patient populations across trials, the model was only able to compare ibrutinib with temsirolimus. MAIC techniques were not able to adequately adjust for all heterogeneity between trials.
• The use of parametric functions for long-term PFS and OS extrapolations is subject to high uncertainty, given the immaturity of PFS and OS trial data. Alternative parametric fittings were tested in the sensitivity analysis to address this uncertainty.
• Ibrutinib demonstrated better health outcomes for MCL patients with prior therapy compared to temsirolimus, driven by significant improvements in PFS and OS.
• This analysis will be updated when results of ibrutinib's Phase III RAY (NCT01646021) are released to further inform ibrutinib's role in this setting. 
